3 results about "Heparin Derivative" patented technology

The invention discloses a contrast agent for enhancing an ELCA volume reduction effect, belongs to the field of medical reagents, and particularly relates to a contrast agent, which comprises a heparin-based compound and a contrast agent, the heparin-based compound comprises heparin, and the content of the heparin-based compound in the contrast agent is 2-64 [mu] g / mL. The contrast agent comprises at least one of iopromide and iodixanol. The heparin-based compound further comprises a heparin derivative, the heparin derivative is prepared by oxidizing heparin and then reacting with a derivating agent, and the derivating agent comprises L-alanyl-L-proline methyl ester hydrochloride. The contrast agent provided by the invention can be combined with ELCA for use, enhances the volume reduction effect of ELCA, has a good ablation effect on vascular plaques, and has high shock wave pressure when acting with excimer laser.

The application discloses a contrast agent for enhancing the effect of ELCA volume reduction, and belongs to the field of medical reagents, and particularly relates to a contrast agent which comprises a heparin-based compound and a contrast agent, wherein the heparin-based compound comprises heparin, and the content of the heparin-based compound in the contrast agent is 2-64 mu g / mL. The contrast agent comprises at least one of iopromide and iodixanol. The heparin-based compound further comprises a heparin derivative, and the heparin derivative is prepared by subjecting heparin to oxidation and then to reaction with a derivatizing agent. The derivatizing agent comprises L-alanyl-L-proline methyl ester hydrochloride. The application is a contrast agent which can be combined with ELCA, enhances the effect of ELCA volume reduction, has a good effect on blood vessel plaque erosion, and has high shock wave pressure when combined with excimer laser.

The present invention is directed to the use of the heparin derivative tafoxiparin in the treatment of preeclampsia (PE). The treatment may be monotherapy or combination therapy, where tafoxiparin is used in combination with an agent (drug) used as standard of care therapy in preeclampsia (PE).